Maria de Santis, Neal D. Shore, Hiroyuki Nishiyama, Michal Krawczyński, Artur Seyitkuliev, Félix Guerrero-Ramos, Ruslan Zukov, Takashi Kawahara, Lieven Goeman, Thomas Powles, Kilian Martin Gust, Susan Feyerabend, Manish Patel, Girish S. Kulkarni, Thierry Lebret, Hans M. Westgeest, Ana Quartilho, Aleksandra Dabrowska, Angie Marsh, Joan Palou. "Durvalumab (D) in combination with BCG induction and maintenance (I + M) therapy for BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.4624